TLDR
- Canopy Growth stock jumped 24% after President Trump said his administration will consider rescheduling cannabis
- The stock currently trades at $1.57 CAD with a market cap of $537 million on the Toronto Stock Exchange
- Canopy Growth reported Q2 2026 results with $66.68 million CAD in revenue and beat earnings expectations by $0.17 CAD
- The company has dropped 68.28% over the past year despite the recent rally
- Canopy Growth closed at $1.59 CAD on December 11, 2025, down 1.26% from the previous session
Canopy Growth Corporation’s stock climbed 24% after President Trump announced his administration would consider changing cannabis classification. The Canadian cannabis producer led a sector-wide rally as traders reacted to the potential policy shift.
Canopy Growth Corporation, CGC
The surge came after Trump’s public statement about reconsidering cannabis scheduling at the federal level. His comments sparked immediate buying across cannabis stocks trading in both Canada and the United States.
Canopy Growth trades under ticker symbol WEED on the Toronto Stock Exchange and CGC on Nasdaq. The company currently sits at $1.57 CAD per share with a market cap of $537.25 million.
The stock has been on a rough ride lately. Over the past 12 months, shares have plunged 68.28% from previous highs.
Canopy Growth’s 52-week trading range stretches from $1.085 to $4.950 per share. Daily volume hit 846,354 shares during the rally, still below the average of 1,508,194 shares.
The Smiths Falls, Ontario-based company produces and sells cannabis, hemp, and related products across Canada, Germany, and Australia. Its product lineup includes dried flower, pre-rolled joints, extracts, edibles, vapes, and oils.
Brands like Tweed and 7ACRES sit in Canopy Growth’s portfolio. The company operates through four business segments and employs 960 people.
Recent Financial Performance
Four weeks ago, Canopy Growth released second quarter fiscal 2026 results. The company brought in $66.68 million CAD in revenue for the quarter ending September 2025.
The loss per share came in at $0.01 CAD. That beat analyst expectations by $0.17 CAD, though revenue missed estimates by $5.14 million CAD.
Full year 2024 revenue totaled $269 million, down 9.47% from 2023’s $297.15 million. Annual losses reached $598.12 million, which was 9% less than the prior year.
Trailing twelve-month revenue stands at $278.61 million. Net losses for that period hit $385.85 million, with earnings per share at negative $2.12.
Product Launches and Growth Plans
Canopy Growth recently rolled out new products to boost margins and cash flow. The company launched Claybourne Gassers Liquid Diamonds vapes in Canada.
In Australia, Canopy Growth expanded its Spectrum Therapeutics line with new softgels. Management has pointed to Canadian cannabis momentum as a key driver for improvement.
The cannabis sector saw broad gains following Trump’s announcement. However, experts warn that cannabis stocks remain highly volatile.
Policy changes around U.S. cannabis rescheduling are still uncertain. The Trump administration’s consideration of the issue has created speculation, but no concrete action has been taken.
Canopy Growth’s next earnings report is scheduled for February 6, 2026. The company closed at $1.59 CAD on December 11, 2025, down $0.020 or 1.26% from the previous trading session.
The post Canopy Growth (CGC) Stock: Cannabis Producer Jumps 24% on Trump Rescheduling Comments appeared first on Blockonomi.